Braveheart Bio to Present at 44th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 6, 2026 /PRNewswire/ -- Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions, today announced that the company will participate in the 44^th Annual J.P. Morgan Healthcare Conference, being held January 12-15 in San Francisco.

Travis Murdoch, M.D., Chief Executive Officer and President of Braveheart Bio, will present an overview of the company on Tuesday, January 13, 2026, at 7:30 a.m. PT / 10:30 a.m. ET. A webcast will be available on the Braveheart website – www.braveheart.bio – and an archived version will be available following the presentation.

About Braveheart Bio

Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital) and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care. For more information, visit www.braveheart.bio.

Contact
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/braveheart-bio-to-present-at-44th-annual-jp-morgan-healthcare-conference-302653274.html

SOURCE Braveheart Bio